{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:16:00Z","timestamp":1790154960700,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.canlet.2013.05.006","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T11:46:16Z","timestamp":1368531976000},"page":"237-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin \u03b11\u2013thymopentin fusion peptide and its binding to TLR2"],"prefix":"10.1016","volume":"337","author":[{"given":"Juan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2013.05.006_b0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.imbio.2012.05.023","article-title":"Thymic peptides restrain the inflammatory response in mice with experimental autoimmune encephalomyelitis","volume":"218","author":"Lunin","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.canlet.2013.05.006_b0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02786456","article-title":"Thymopentin and splenopentin as immunomodulators, current status","volume":"17","author":"Singh","year":"1998","journal-title":"Immunol. Res."},{"key":"10.1016\/j.canlet.2013.05.006_b0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00008390-199802000-00014","article-title":"Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients","volume":"8","author":"Cascinelli","year":"1998","journal-title":"Melanoma Res."},{"key":"10.1016\/j.canlet.2013.05.006_b0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1440-1746.2008.05387.x","article-title":"Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study","volume":"23","author":"Lee","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2013.05.006_b0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12072-008-9046-5","article-title":"Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B","volume":"2","author":"Piratvisuth","year":"2008","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.canlet.2013.05.006_b0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1665-2681(19)31839-3","article-title":"Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders","volume":"7","author":"Poo","year":"2008","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.canlet.2013.05.006_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijpharm.2009.10.045","article-title":"Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels","volume":"386","author":"Zhang","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2013.05.006_b0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/archotol.1989.01860350079019","article-title":"Interleukin 2 receptor expression in patients with head and neck squamous carcinoma.Effects of thymosin alpha 1 in vitro","volume":"115","author":"Wolf","year":"1989","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.canlet.2013.05.006_b0045","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0192-0561(00)00065-5","article-title":"Thymosin a1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro","volume":"22","author":"Baumann","year":"2000","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.canlet.2013.05.006_b0050","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00262-010-0862-9","article-title":"Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris","volume":"59","author":"Chen","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2013.05.006_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0304-3835(00)00510-3","article-title":"Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB\/c-mice","volume":"159","author":"Beuth","year":"2000","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2013.05.006_b0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1196\/annals.1415.040","article-title":"Thymosin alpha1 as a chemopreventive agent in lung and breast cancer","volume":"1112","author":"Moody","year":"2007","journal-title":"Ann. NY. Acad. Sci."},{"key":"10.1016\/j.canlet.2013.05.006_b0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ijc.2910500327","article-title":"Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice","volume":"50","author":"Mastino","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.05.006_b0070","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1567-5769(03)00053-5","article-title":"Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer","volume":"3","author":"Garaci","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2013.05.006_b0075","doi-asserted-by":"crossref","first-page":"302084","DOI":"10.1155\/2009\/302084","article-title":"Potential role of thymosin-alpha 1 adjuvant therapy for glioblastoma","volume":"2009","author":"Sungarian","year":"2009","journal-title":"J. Oncol."},{"key":"10.1016\/j.canlet.2013.05.006_b0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cellimm.2009.05.002","article-title":"Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus","volume":"258","author":"Liu","year":"2009","journal-title":"Cell Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ptr.1948","article-title":"Pretreatment with neem (Azadirachta indica) leaf preparation in Swiss mice diminishes leukopenia and enhances the antitumor activity of cyclophosphamide","volume":"20","author":"Ghosh","year":"2006","journal-title":"Phytother. Res."},{"key":"10.1016\/j.canlet.2013.05.006_b0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0008-8749(85)90051-6","article-title":"Receptors for thymosin alpha 1 on mouse thymocytes","volume":"91","author":"Rinaldi Garaci","year":"1985","journal-title":"Cell Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0095","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2003-11-4036","article-title":"Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling","volume":"103","author":"Romani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2013.05.006_b0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1196\/annals.1415.025","article-title":"Signaling pathways leading to the activation of IKK and MAPK by thymosin alpha","volume":"1112","author":"Peng","year":"2007","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.canlet.2013.05.006_b0105","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s12272-001-2132-z","article-title":"Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization","volume":"31","author":"Gao","year":"2008","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.canlet.2013.05.006_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2012.04.013","article-title":"Intein-mediated expression, purification, and characterization of thymosin alpha1-thymopentin fusion peptide in Escherichia coli","volume":"84","author":"Li","year":"2012","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.canlet.2013.05.006_b0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4049\/jimmunol.162.1.314","article-title":"A NF-kappa B\/c-myc-dependent survival pathway is targeted by corticosteroids in immature thymocytes","volume":"162","author":"Wang","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0120","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.4049\/jimmunol.160.5.2231","article-title":"Corticosteroids enhance the capacity of macrophages to induce Th2 cytokines synthesis in CD41 lymphocytes by inhibiting IL-12 production","volume":"160","author":"De Kruyff","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0125","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1016\/S0021-9258(18)53268-3","article-title":"The structure and mechanism of formation of human calcitonin fibrils","volume":"268","author":"Arvinte","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2013.05.006_b0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1567-5769(01)00139-4","article-title":"Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1","volume":"2","author":"Sodhi","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2013.05.006_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10540-006-9012-1","article-title":"Synergistic effect between ouabain and glucocorticoids for the induction of thymic atrophy","volume":"26","author":"Rodrigues-Mascarenhas","year":"2006","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.canlet.2013.05.006_b0140","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.4049\/jimmunol.158.12.5589","article-title":"Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes","volume":"158","author":"Blotta","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/37.suppl_C.21","article-title":"Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues","volume":"37","author":"Girard","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.canlet.2013.05.006_b0150","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0196-9781(02)00025-6","article-title":"Thymosin 1 inhibits mammary carcinogenesis in Fisher rats","volume":"23","author":"Moody","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.canlet.2013.05.006_b0155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ijc.2910570516","article-title":"Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats","volume":"57","author":"Rasi","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.05.006_b0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0074-7696(07)56005-5","article-title":"MHC class I antigens and immune surveillance in transformed cells","volume":"256","author":"Aptsiauri","year":"2007","journal-title":"Int. Rev. Cytol."},{"key":"10.1016\/j.canlet.2013.05.006_b0165","first-page":"1095","article-title":"Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells","volume":"61","author":"Seliger","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.05.006_b0170","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO;2-I","article-title":"Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level","volume":"30","author":"Giuliani","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2013.05.006_b0180","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.3748\/wjg.v12.i45.7233","article-title":"Colon cancer and the immune system: the role of tumor invading T cells","volume":"12","author":"Waldner","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2013.05.006_b0185","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1073\/pnas.0400171101","article-title":"TLR2 is expressed on activated T cells as a costimulatory receptor","volume":"101","author":"Komai-Koma","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2013.05.006_b0190","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.4049\/jimmunol.1002320","article-title":"TLR1\/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells","volume":"186","author":"Zhang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2013.05.006_b0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0958-1669(97)80157-7","article-title":"Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors","volume":"8","author":"Myszka","year":"1997","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.canlet.2013.05.006_b0200","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1074\/jbc.M806633200","article-title":"Binding and cellular activation studies reveal that toll-like receptor 2 can differentially recognize peptidoglycan from gram-positive and gram-negative bacteria","volume":"284","author":"Asong","year":"2009","journal-title":"J. Biol. Chem."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513003753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513003753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T18:45:28Z","timestamp":1688237128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513003753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0304383513003753"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.05.006","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin \u03b11\u2013thymopentin fusion peptide and its binding to TLR2","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}